Denali Therapeutics Inc (NASDAQ: DNLI) kicked off on Tuesday, up 5.06% from the previous trading day, before settling in for the closing price of $21.93. Over the past 52 weeks, DNLI has traded in a range of $14.56-$33.33.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
Healthcare Sector giant saw their annual sales surged by 350.08% over the last five years. While this was happening, its average annual earnings per share was recorded -162.05%. With a float of $124.59 million, this company’s outstanding shares have now reached $143.84 million.
The firm has a total of 445 workers. Let’s measure their productivity. In terms of profitability, gross margin is 102.06%, operating margin of 165.42%, and the pretax margin is 140.13%.
Denali Therapeutics Inc (DNLI) Breakdown of a Key Holders of the stock
Our next focus will be how large-scale investors are participating in this stock of the Biotechnology Industry. The insider ownership of Denali Therapeutics Inc is 13.43%, while institutional ownership is 88.50%. The most recent insider transaction that took place on Jan 06 ’25, was worth 247,796. In this transaction Chief Medical Officer of this company sold 12,255 shares at a rate of $20.22, taking the stock ownership to the 178,580 shares. Before that another transaction happened on Jan 07 ’25, when Company’s Chief Medical Officer sold 2,907 for $20.81, making the entire transaction worth $60,495. This insider now owns 175,673 shares in total.
Denali Therapeutics Inc (DNLI) Recent Fiscal highlights
Wall Street market experts anticipate that the next fiscal year will bring earnings of -0.85 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around -162.05% per share during the next fiscal year.
Denali Therapeutics Inc (NASDAQ: DNLI) Trading Performance Indicators
Take a look at Denali Therapeutics Inc’s (DNLI) current performance indicators. Last quarter, stock had a quick ratio of 9.98.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -2.76, a number that is poised to hit -0.82 in the next quarter and is forecasted to reach -2.98 in one year’s time.
Technical Analysis of Denali Therapeutics Inc (DNLI)
Analysing the last 5-days average volume posted by the [Denali Therapeutics Inc, DNLI], we can find that recorded value of 1.17 million was better than the volume posted last year of 1.16 million. As of the previous 9 days, the stock’s Stochastic %D was 90.37%. Additionally, its Average True Range was 1.36.
During the past 100 days, Denali Therapeutics Inc’s (DNLI) raw stochastic average was set at 30.52%, which indicates a significant decrease from 93.97% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 90.08% in the past 14 days, which was higher than the 59.93% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $23.65, while its 200-day Moving Average is $23.12. Now, the first resistance to watch is $23.56. This is followed by the second major resistance level at $24.09. The third major resistance level sits at $24.84. If the price goes on to break the first support level at $22.28, it is likely to go to the next support level at $21.53. Now, if the price goes above the second support level, the third support stands at $21.00.
Denali Therapeutics Inc (NASDAQ: DNLI) Key Stats
The company with the Market Capitalisation of 3.32 billion has total of 143,922K Shares Outstanding. Its annual sales at the moment are 330,530 K in contrast with the sum of -145,220 K annual income. Company’s last quarter sales were recorded 0 K and last quarter income was -107,190 K.
